Slider 7 About
Patented new technology which takes breast sizes and stiffness into account.
Slider 5 About
Clear visual guideline for
every breast compression.
Slider 9 About
Prevent under- and over-compression of the breast by standardization on pressure.

About Sigmascreening

Sigmascreening, an Amsterdam based medical device company focusing on the development of new innovative products in the area of digital mammography and breast cancer screening. Sigmascreening is established as a spin-off company from the Academic Medical Center Amsterdam (AMC Amsterdam).

 

Sigmascreening has several products under development. The Sensitive Sigma™ Paddle is our new CE-certified product, based on our patented technology. It optimizes compression for every single breast and takes breast sizes and stiffness into account, preventing unnecessary discomfort or pain. A highly reproducible procedure with a same physical experience, year after year.

 

We aim to introduce new products that will improve mammography and contribute to the early detection of cancer which ultimately can saves lives.

The Team


Monique van Lier

Clinical Application Specialist - Monique van Lier studied Technical Medicine at the University of Twente and obtained her MSc in the mastertrack Robotics & Imaging. Monique provides training to technicians and helps them to further improve their daily breast examinations with the unique Sensitive Sigma Paddle technology.

Kees Grimbergen
Chief Technology Officer (CTO) - Kees started his career in Groningen finalizing a thesis in Solid State Physics in 1977. Kees works on many projects in the field of instrumentation, signal analysis and medical imaging at the AMC Dept. of Biomedical Engineering & Physics. Kees holds a professorship in Medical Technology since 1995 and has part-time appointment at the Delft University of Technology.
Ard den Heeten
Co-founder of Sigmascreening - Ard has been a radiologist for more then 30 years. After 10 years of general radiology, he became professor in Radiology in 1998 in the AMC, Amsterdam. He is a former chair of the Dutch Radiological Society. From 2005 until July 2015 he was also engaged in the National Breast Cancer Screening program as director of the National Reference and Training Centre. Ard officially retired, but is since January 2016 employed by Sigmascreening for one day per week to further improve mammography by pressure based breast compression.
Ivo Aarninkhof
Chief Executive Officer (CEO) - Ivo Aarninkhof held senior management positions for Philips in general management, marketing, supply chain management, product dev. and plant management across Europe and China for over 13 years. Until 2008 Ivo worked as Director Product Marketing for Radiography in Hamburg Germany. Until 2011 he was responsible as Senior Director and General Manager for Diagnostic Xray in Shanghai China. Ivo holds a MSc. degree from the University of Twente and an executive MBA.
Jerry de Groot
Research and development - Jerry de Groot studied applied physics in Enschede and graduated on laser Doppler perfusion techniques in 2007. After a year of orientation in teaching physics in high school, Jerry re-focussed on research and development for Sigmascreening. In June 2015 he successfully defended his PhD thesis "Pressure-standardized breast compression in mammography".
Woutjan Branderhorst

Research and development - Woutjan Branderhorst obtained a MSc degree in computer science from Eindhoven University of Technology and a PhD degree in medical imaging from the Image Sciences Institute (UMC Utrecht). Under supervision of prof. Freek J. Beekman and prof. Max A. Viergever, he has worked on medical imaging device development and validation, resulting in his PhD thesis "Focused multi-pinhole SPECT".

Ben Hendriks
Technical/commercial project manager, Germany - Ben Hendriks has been working as technical/commercial project manager at leading international companies for decades. As a project manager and temporary management team delegate he regularly fulfils a counselling role between (management) layers. He performs the job, however, in his own – unique – way: by analysing but above all by adopting a solution-oriented approach. As Business Development Manager Ben has a broad experience and is focussed on introduction and market development of The Sensitive Sigma Paddle for the German-speaking countries. He uses his experience, values and expertise to bridge the cultural differences and to further improve mammography by pressure based breast compression 

The Supervisory Board


Jan Egberts
Chairman of Supervisory Board – Jan H. Egberts, M.D. has over 25 years of experience in the pharmaceutical and medical devices sector. Dr Egberts gained his medical qualifications from Erasmus University Medical School in the Netherlands and obtained his MBA from Stanford. After Stanford, he joined McKinsey & Co. as a strategic consultant in New York.  Dr Egberts subsequently held various business development and general management positions of increasing responsibility in the USA at Merck & Co. and Johnson & Johnson.  While at Johnson & Johnson, he initiated the leveraged buy out of the BARRIER surgical business from Johnson & Johnson and the subsequent merger with Mölnlycke Health Care. After the divestiture of Molnlycke Health Care to Regent Medical he served as Senior Advisor, Healthcare Investments for 3i, the private equity firm. After his move to the Netherlands, Dr Egberts became CEO of OctoPlus, a publicly traded specialty pharmaceutical company in the Netherlands. OctoPlus was subsequently acquired by Dr Reddy Laboratories from India. After this acquisition, Dr Egberts joined Agendia, a molecular diagnostics company, initially as board member and subsequently full time as interim CEO.  Currently, Dr Egberts serves as the Managing Partner of Veritas Investments, a private investment company focused on minority and controlling investments in healthcare companies. Dr Egberts also has held over 15 executive and non-executive supervisory board positions in the U.S.A. and various European countries.
Jaap Maljers
Board member - Jaap Maljers studied medicine at the University of Amsterdam and obtained his MBA at the Rotterdam School of Management. He joined McKinsey & company in 1987 (Brussels and Amsterdam). In 1991 he started his own consultancy Plexus. Specialized in health care and very strong focus on medical content Plexus became the market leader in The Netherlands. In 2011 he sold Plexus to KPMG. Meanwhile he developed as an entrepreneur. Using his consultancy as a platform Jaap founded ZorgDomein (an advanced referral system used by more than 90% of Dutch GP’s) and Performation (big data analysis for hospitals). In 1997 he was one of the first to establish private clinics in the Netherlands (Vision Clinics and Alant Medical). In 2009 he merged all his clinical activities with Bergman Clinics, with 23 clinics the largest private care provider. Jaap is co-owner an non-executive at Bergman. 2010 he joined Holland Venture to become member of the investment committee. He is chairman of the Dutch Child Cancer Foundation (KiKa) and member of the supervisory board of the CPB (governmental Planning Agency).
Christiaan Neeleman
Board member – Christiaan Neeleman has more than 25 years of general management experience, with a focus on healthcare imaging. Currently he is Chief Operating Officer at Definiens AG, a company focusing on tissue based diagnostics in Oncology. Prior to joining Definiens, Mr. Neeleman was the COO Product Group Lithography Applications for ASML. He also was responsible for the global X-Ray Systems Business of Philips Healthcare – comprising Radiography, Fluoroscopy, Mammography and Surgical C-arms – after having led the Components Business. During his tenure at ASML and Philips Healthcare, Mr. Neeleman transformed businesses towards profitable growth, focusing on new markets, new technologies, efficiency, and teamwork. Mr. Neeleman also held management roles in Philips’ mobile display business, and prior to that in Mettler Toledo. Mr. Neeleman has an M.Sc. degree in Micro Mechanical Engineering from the Technical University Delft and an MBA from INSEAD.
Harm de Vries
Board member - General Partner and co-founder of venture capital funds targeting early stage high tech companies and university spinouts that develop commercially promising products and technologies in technology areas such as life sciences, cleantechnology, nanotechnology, and ICT. The funds under management are the Erasmus MC Biomedical Fund (Rotterdam, 2007), the Life Sciences Fund Amsterdam (Amsterdam, 2009), and the Twente Technology Fund (Enschede, 2010). All funds are independent and have unique access to the Universities within their focal regions, including the Erasmus University Rotterdam, the AMC Amsterdam, the Free University MC, the Dutch Cancer Institute, Sanquin and the Technical University of Twente.
Ben Dijk
Board Member – Ben Dijk is Investment Director at DFZ Participaties, a captive venture fund of health insurance company De Friesland specially dedicated to healthcare innovations. Prior to DFZ Participaties he was an Investment Manager at Friesland Bank Investments, a private equity fund with a focus on medium sized companies. He was also advising the management board on the strategic portfolio of Friesland Bank. Before that he was responsible for building positions in listed small & medium sized companies. Ben holds a master in Business Administration from the University of Groningen.